GH Research PLC (NASDAQ:GHRS) Stake Cut by Barclays PLC

Barclays PLC lessened its holdings in GH Research PLC (NASDAQ:GHRS) by 69.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,984 shares of the company’s stock after selling 13,925 shares during the quarter. Barclays PLC’s holdings in GH Research were worth $40,000 at the end of the most recent quarter.

Separately, RA Capital Management L.P. increased its stake in shares of GH Research by 1.3% in the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after purchasing an additional 85,000 shares during the period. Institutional investors own 56.90% of the company’s stock.

GH Research Price Performance

GHRS stock opened at $8.83 on Friday. GH Research PLC has a 52-week low of $6.00 and a 52-week high of $14.99. The firm has a market capitalization of $459.42 million, a P/E ratio of -11.18 and a beta of 0.84. The company’s 50 day simple moving average is $8.42 and its 200-day simple moving average is $8.97.

Analyst Ratings Changes

GHRS has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Friday, January 10th. Canaccord Genuity Group reduced their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).